Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLS001
- Development stage
- Unknown
- Lead developer
- Cellusion
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic, Topical
01
Overview
CLS001 is an induced pluripotent stem cell (iPSC)-derived corneal endothelial cell therapy developed by Cellusion for the treatment of bullous keratopathy. Bullous keratopathy is a condition characterized by corneal edema and vision loss due to the dysfunction or depletion of corneal endothelial cells. CLS001 aims to address the global shortage of donor corneas by providing a mass-produced, standardized alternative to traditional corneal transplantation. The therapy involves the injection of iPSC-derived corneal endothelial substitute cells into the anterior chamber of the eye. It has demonstrated safety and efficacy in first-in-human studies and is advancing into Phase 1/2 clinical trials in Japan and globally.
- Other names
- iPSC-derived corneal endothelial cellsiCECSiPSC-derived corneal endothelial cell substitute
Beyond the preview
Go deeper on CLS001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLS001.